Literature DB >> 8264769

Antibody raised against extracellular proteinases of Sporothrix schenckii in S. schenckii inoculated hairless mice.

T Yoshiike1, P C Lei, H Komatsuzaki, H Ogawa.   

Abstract

Sporothrix schenckii produces two extracellular proteinases, namely proteinase I and II. Proteinase I is a serine proteinase, inhibited by chymostatin, while proteinase II is an aspartic proteinase, inhibited by pepstatin. Studies on substrate specificity and the effect of proteinase inhibitors on cell growth suggest an important role for these proteinases in terms of fungal invasion and growth. There has, however, been no evidence presented demonstrating that S. schenckii produces 2 extracellular proteinases in vivo. In order to substantiate the in vivo production of proteinases and to attempt a preliminary serodiagnosis of sporotrichosis, serum antibodies against 2 proteinases were assayed using S. schenckii inoculated hairless mice. Subsequent to an intracutaneous injection of S. schenckii to the mouse skin, nodules spontaneously formed and disappeared for a period of 4 weeks. Histopathological examination results were in accordance with the microscopic observations. Micro-organisms disappeared during the fourth week. Serum antibody titers against purified proteinases I and II were measured weekly, using enzyme-linked immunosorbent assay (EIA). As a result, the time course of the antibody titers to both proteinases I and II were parallel to that of macroscopic and microscopic observations in an experimental mouse sporotrichosis model. These results suggest that S. schenckii produces both proteinases I and II in vivo. Moreover, the detection of antibodies against these proteinases can contribute to a serodiagnosis of sporotrichosis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8264769     DOI: 10.1007/bf01365082

Source DB:  PubMed          Journal:  Mycopathologia        ISSN: 0301-486X            Impact factor:   2.574


  17 in total

1.  Pulmonary sporotrichosis. Report of two cases with cavitation.

Authors:  S M SCOTT; E D PEASLEY; T P CRYMES
Journal:  N Engl J Med       Date:  1961-09-07       Impact factor: 91.245

2.  Pulmonary sporotrichosis.

Authors:  G W POST; A JACKSON; P E GARBER; G E VEACH
Journal:  Dis Chest       Date:  1958-10

3.  Sporothrix whole yeast agglutination test: low-titer reactions of sera of subjects not known to have sporotrichosis.

Authors:  R D Welsh; C T Dolan
Journal:  Am J Clin Pathol       Date:  1973-01       Impact factor: 2.493

4.  IgG production within the central nervous system: a critical review of proposed formulae.

Authors:  A K Lefvert; H Link
Journal:  Ann Neurol       Date:  1985-01       Impact factor: 10.422

5.  Isolation and purification of a peptido-rhamnomannan from the yeast form of Sporothrix schenckii. Structural and immunochemical studies.

Authors:  K O Lloyd; M A Bitoon
Journal:  J Immunol       Date:  1971-09       Impact factor: 5.422

6.  Serologic aspects of sporotrichosis.

Authors:  J V Karlin; H S Nielsen
Journal:  J Infect Dis       Date:  1970-03       Impact factor: 5.226

7.  Correlation between culture medium pH, extracellular proteinase activity, and cell growth of Candida albicans in insoluble stratum corneum-supplemented media.

Authors:  R Tsuboi; K Matsuda; I J Ko; H Ogawa
Journal:  Arch Dermatol Res       Date:  1989       Impact factor: 3.017

8.  Influence of culture medium pH and proteinase inhibitors on extracellular proteinase activity and cell growth of Sporothrix schenckii.

Authors:  R Tsuboi; T Sanada; H Ogawa
Journal:  J Clin Microbiol       Date:  1988-07       Impact factor: 5.948

9.  Serologic studies in the diagnosis and management of meningitis due to Sporothrix schenckii.

Authors:  E N Scott; L Kaufman; A C Brown; H G Muchmore
Journal:  N Engl J Med       Date:  1987-10-08       Impact factor: 91.245

10.  Keratinolytic proteinase produced by Candida albicans.

Authors:  M Hattori; K Yoshiura; M Negi; H Ogawa
Journal:  Sabouraudia       Date:  1984
View more
  6 in total

1.  Adenosine deaminase activity in serum and lymphocytes of rats infected with Sporothrix schenckii.

Authors:  Verônica S P Castro; Victor C Pimentel; Aleksandro S Da Silva; Gustavo R Thomé; Patrícia Wolkmer; Jorge L C Castro; Márcio M Costa; Cássia B da Silva; Daniele C Oliveira; Sydney H Alves; Maria R C Schetinger; Sonia T A Lopes; Cinthia M Mazzanti
Journal:  Mycopathologia       Date:  2011-12-15       Impact factor: 2.574

Review 2.  Virulence factors of medically important fungi.

Authors:  L H Hogan; B S Klein; S M Levitz
Journal:  Clin Microbiol Rev       Date:  1996-10       Impact factor: 26.132

3.  Differences in virulence between isolates of feline Sporotrichosis.

Authors:  Márcia de Oliveira Nobre; Tatiana de Avila Antunes; Renata Osório de Faria; Marlete Brum Cleff; Cristina Gevehr Fernandes; Adriana Cunha Muschner; Mário Carlos Araújo Meireles; Laerte Ferreiro
Journal:  Mycopathologia       Date:  2005-08       Impact factor: 2.574

Review 4.  Current research on the immune response to experimental sporotrichosis.

Authors:  Iracilda Zeppone Carlos; Micheli Fernanda Sassá; Diana Bridon da Graça Sgarbi; Marisa Campos Polesi Placeres; Danielle Cardoso Geraldo Maia
Journal:  Mycopathologia       Date:  2009-02-25       Impact factor: 2.574

5.  Differences in cell morphometry, cell wall topography and gp70 expression correlate with the virulence of Sporothrix brasiliensis clinical isolates.

Authors:  Rafaela A Castro; Paula H Kubitschek-Barreira; Pedro A C Teixeira; Glenda F Sanches; Marcus M Teixeira; Leonardo P Quintella; Sandro R Almeida; Rosane O Costa; Zoilo P Camargo; Maria S S Felipe; Wanderley de Souza; Leila M Lopes-Bezerra
Journal:  PLoS One       Date:  2013-10-07       Impact factor: 3.240

Review 6.  Virulence Factors of Sporothrix schenckii.

Authors:  Laura Cristina García-Carnero; José Ascención Martínez-Álvarez
Journal:  J Fungi (Basel)       Date:  2022-03-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.